Entries by raincastle
RAC1 plays an essential role in estrogen receptor alpha function in breast cancer cells. Oncogene. 2021.
Sun, J., Gaidosh, G, Xu, Y, Mookhtiar, A, Goka, ET, Lippman, ME, et al.
Hormone dependent prostate cancers are dependent on Rac signaling for growth and survival. Mol Cancer Ther. 2021; 20(6): 1052-1061.
Erik T. Goka, Dayrelis T. Mesa Lopez and Marc E. Lippman
Rac signaling drives clear cell renal cell carcinoma tumor growth by priming the tumor microenvironment for an angiogenic switch. Mol Cancer Ther. 2020; 19(7): 1462-1473.
Erik T. Goka, Dayrelis T. Mesa Lopez and Marc E. Lippman
Rac1b overexpression confers resistance to chemotherapy treatment in colorectal cancer. Mol Cancer Ther. 2019; 10(5):,957-968.
Erik T. Goka, Dayrelis T. Mesa Lopez and Marc E. Lippman
Loss of the E3 ubiquitin ligase HACE1 results in enhanced Rac1 signaling contributing to breast cancer progression. Oncogene. 2016; 34(42): 5395-5405.
Erik T. Goka, Dayrelis T. Mesa Lopez and Marc E. Lippman
Revere Pharma Announces Publication of Research that Elaborates Role of Rac1 in Prostate Cancer
Research conducted by Dr. Erik Goka and published in Molecular Cancer Therapeutics demonstrates that Rac1 inhibition can attenuate the growth and survival of prostate cancer cells Boston, Mass. — Revere Pharmaceuticals, an emerging biopharmaceutical company developing small molecule drugs targeting key signaling proteins to treat cancer and other disease, announced the publication of research results […]
Revere Pharmaceuticals Announces Asset Purchase Agreement to Acquire All Assets of Geneyus LLC
Revere becomes the leader in developing drugs targeting Rho GTPases with consolidation of key assets pertaining to Rac1, including a drug discovery platform and promising preclinical programs Boston, Mass. — Revere Pharmaceuticals, an emerging biopharmaceutical company developing small molecule drugs targeting the Ras-homologous (Rho) family GTPases, announced the completion of an Asset Purchase Agreement to […]
Revere Pharmaceuticals Expands Board of Directors to Include Marc Lippman, MD
Renown cancer researcher and biotech veteran brings expertise in developing novel cancer therapeutics in emerging biotech companies Boston, Mass. — Revere Pharmaceuticals, an emerging biopharmaceutical company developing small molecule drugs targeting the Ras-homologous (Rho) family GTPases, announced today that in connection with Revere’s Asset and Purchase Agreement with Geneyus, Marc Lippman, MD, MACP, FRCP has […]